Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Status
Active
Cancer Type
Hodgkin Lymphoma
Trial Phase
Phase II
Eligibility
60 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01716806
Protocol IDs
SGN35-015 (primary)
Study Sponsor
Seattle Genetics, Incorporated

Summary

This is a single-arm, open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin as front-line therapy in adults age 60 and above with HL.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.